Oliver Jonas

Oliver Jonas

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NCNimrat Chatterjee
Nimrat Chatterjee
MWMatthew A. Whitman
Matthew A. Whitman
CHCynthia A. Harris
Cynthia A. Harris
SMSophia M. Min
Sophia M. Min
OJOliver Jonas
Oliver Jonas
GWGraham C. Walker
Graham C. Walker
Significance: Mutagenic translesion synthesis (TLS) increases cell survival after DNA damage by bypassing lesions that normally block DNA replication but introduces mutations. In cancer cells, REV1/POLζ-dependent mutagenic TLS can contribute to intrinsic chemoresistance, while the mutations it introduces can underlie acquired chemoresistance. Interfering with this TLS pathway genetically or with the small molecule inhibitor JH-RE-06 has been shown to improve cisplatin chemotherapy by suppressing tumor growth and enhancing survival in mouse xenograft tumor models. Cisplatin chemotherapy commonly exerts its antitumor effects via DNA damage-mediated apoptosis. However, in two mouse xenograft models and four mammalian cell lines, the JH-RE-06 unexpectedly profoundly alters the biological response to cisplatin. Apoptosis is suppressed and surprisingly numerous hallmarks of senescence are induced prior to cell death.

4 July 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
ZTZuzana Tatarova
Zuzana Tatarova
DBDylan C. Blumberg
Dylan C. Blumberg
JKJames E. Korkola
James E. Korkola
LHLaura M. Heiser
Laura M. Heiser
JMJohn L. Muschler
John L. Muschler
JGJoe W. Gray
Joe W. Gray
Systematically identifying synergistic combinations of targeted agents and immunotherapies for cancer treatments remains difficult. In this study, we integrated high-throughput and high-content techniques—an implantable microdevice to administer multiple drugs into different sites in tumors at nanodoses and multiplexed imaging of tumor microenvironmental states—to investigate the tumor cell and immunological response signatures to different treatment regimens. Using a mouse model of breast cancer, we identified effective combinations from among numerous agents within days. In vivo studies in three immunocompetent mammary carcinoma models demonstrated that the predicted combinations synergistically increased therapeutic efficacy. We identified at least five promising treatment strategies, of which the panobinostat, venetoclax and anti-CD40 triple therapy was the most effective in inducing complete tumor remission across models. Successful drug combinations increased spatial association of cancer stem cells with dendritic cells during immunogenic cell death, suggesting this as an important mechanism of action in long-term breast cancer control.

21 November 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JPJesse C. Patterson
Jesse C. Patterson
AVAndreas Varkaris
Andreas Varkaris
PCPeter J.P. Croucher
Peter J.P. Croucher
MRMaya Ridinger
Maya Ridinger
SDSusan Dalrymple
Susan Dalrymple
MYMichael B. Yaffe
Michael B. Yaffe
Abiraterone is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) that slows disease progression by abrogating androgen synthesis and antagonizing the androgen receptor (AR). Here we report that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the clinically active third-generation Plk1 inhibitor onvansertib, synergizes with abiraterone in vitro and in vivo to kill a subset of cancer cells from a wide variety of tumor types in an androgen-independent manner. Gene-expression analysis identified an AR-independent synergy-specific gene set signature upregulated upon abiraterone treatment that is dominated by pathways related to mitosis and the mitotic spindle. Abiraterone treatment alone caused defects in mitotic spindle orientation, failure of complete chromosome condensation, and improper cell division independently of its effects on AR signaling. These effects, although mild following abiraterone monotherapy, resulted in profound sensitization to the antimitotic effects of Plk1 inhibition, leading to spindle assembly checkpoint-dependent mitotic cancer cell death and entosis. In a murine patient-derived xenograft model of abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC), combined onvansertib and abiraterone resulted in enhanced mitotic arrest and dramatic inhibition of tumor cell growth compared with either agent alone. Overall, this work establishes a mechanistic basis for the phase II clinical trial (NCT03414034) testing combined onvansertib and abiraterone in mCRPC patients and indicates this combination may have broad utility for cancer treatment. Significance: Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.

6 September 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
PPPierpaolo Peruzzi
Pierpaolo Peruzzi
CDChristine Dominas
Christine Dominas
GFGeoffrey Fell
Geoffrey Fell
JBJoshua Bernstock
Joshua Bernstock
SBSarah E Blitz
Sarah E Blitz
OJOliver Jonas
Oliver Jonas
The lack of reliable predictive biomarkers to guide effective therapy is a major obstacle to the advancement of therapy for high-grade gliomas, particularly glioblastoma (GBM), one of the few cancers whose prognosis has not improved over the past several decades. With this pilot clinical trial (number NCT04135807), we provide first-in-human evidence that drug-releasing intratumoral microdevices (IMDs) can be safely and effectively used to obtain patient-specific, high-throughput molecular and histopathological drug response profiling. These data can complement other strategies to inform the selection of drugs based on their observed antitumor effect in situ. IMDs are integrated into surgical practice during tumor resection and remain in situ only for the duration of the otherwise standard operation (2 to 3 hours). None of the six enrolled patients experienced adverse events related to the IMD, and the exposed tissue was usable for downstream analysis for 11 out of 12 retrieved specimens. Analysis of the specimens provided preliminary evidence of the robustness of the readout, compatibility with a wide array of techniques for molecular tissue interrogation, and promising similarities with the available observed clinical-radiological responses to temozolomide. From an investigational aspect, the amount of information obtained with IMDs allows characterization of tissue effects of any drugs of interest, within the physiological context of the intact tumor, and without affecting the standard surgical workflow.

1 April 2020 in Applied Surface Science
Verified
Journal Article
Closed access
ACAhrom Choi
Ahrom Choi
JPJuyun Park
Juyun Park
JKJisoo Kang
Jisoo Kang
OJOliver Jonas
Oliver Jonas
DKDong-Woo Kim
Dong-Woo Kim
YKYong-Cheol Kang
Yong-Cheol Kang

30 July 2018 in The Analyst
Verified
Journal Article
Open access
PDF file
OJOliver Jonas
Oliver Jonas
JKJeon Woong Kang
Jeon Woong Kang
SSSurya P. Singh
Surya P. Singh
ALAlex Lammers
Alex Lammers
FNFreddy Nguyen
Freddy Nguyen
MCMichael J. Cima
Michael J. Cima
We describe a label-free approach based on Raman spectroscopy, to study drug-induced apoptosis in vivo. Spectral-shifts at wavenumbers associated with DNA, proteins, lipids, and collagen have been identified on breast and melanoma tumor tissues. These findings may enable a new analytical method for rapid readout of drug-therapy with miniaturized probes.